Biological Psychiatry. Editor: J. Mendlewicz (Brussels). Original Paper
Decreased Plasma Antioxidants in SchizophreniaPae C.-U. · Paik I.-H. · Lee C. · Lee S.-J. · Kim J.-J. · Lee C.-U.
Department of Psychiatry, Kangnam St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
An aberration in the level of antioxidants has been suggested in schizophrenia. Therefore, this study examined the difference in the antioxidant level between patients with schizophrenia and healthy controls, as well as the difference between the drug-naïve schizophrenic patients with a first episode (FSPR) and the risperidone-treated chronic schizophrenia (RCSPR) patients. The plasma albumin, bilirubin and uric acid levels were determined in 47 FSPR and 55 chronic schizophrenia patients who met the DSM-IV criteria for schizophrenia, and in 68 controls. The albumin and bilirubin levels were significantly lower in the schizophrenic patients compared to the controls, although there was no significant difference between the FSPR and RCSPR patients. The bilirubin level was significantly lower in the negative subgroup of the patient group. This study supports the hypothesis that an aberration in the antioxidant levels may be involved in schizophrenia. In addition, this study suggests that the antioxidant level may be associated with the clinical symptomatology as well as the treatment implications in schizophrenia, particularly the negative symptoms.
© 2004 S. Karger AG, Basel
- Yao JK, Reddy R, McElhinny LG, van Kammen DP: Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998;32:1–8.
Yao JK, van Kammen, Reddy RD, Kelley ME: Superoxide dismutase and negative symptoms in schizophrenia. Biol Psychiatry 1998;43:123S–124S.
- Yao JK, Reddy R, van Kammen DP: Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998;80:29–39.
- Yao JK, Reddy R, van Kammen DP: Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000;97:137–151.
- Reddy R, Keshavan M, Yao JK: Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003;62:205–212.
- Smythies JR: Oxidative reactions and schizophrenia: A review-discussion. Schizophr Res 1997;24:357–364.
- Wong CT, Tsoi WF, Saha N: Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res 1996;22:165–171.
- Ness AR, Cappuccio FP, Atkinson RW, Khaw KT, Cook DG: Plasma vitamin C levels in men and women from different ethnic backgrounds living in England. Int J Epidemiol 1999;28:450–455.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22–33.
- Doumas BT, Watson WA, Biggs HG: Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 1971;31:87–96.
- Pearlman FC, Lee RT: Detection and measurement of total bilirubin in serum, with use of surfactants as solubilizing agents. Clin Chem 1974;20:447–453.
- Gochman N, Schmitz JM: Automated determination of uric acid, with use of a uricase-peroxidase system. Clin Chem 1971;17:1154–1159.
- Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99–110.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.